What is self-medication?
Self-medication means using medication without the supervision of a doctor, or in a way other than prescribed, for example by using a different dosage. In the context of transgender healthcare, this often involves the use of gender-affirming hormones, such as estrogens, anti-androgens or testosterone, without medical supervision1. This is also referred to as Do-It-Yourself Hormone (Replacement) Therapy (DIY H(R)T) or “non-prescribed hormone therapy.2. Self-medication can include, for example:
- Ordering hormonal medication through (foreign) websites or online care providers;
- Using medication prescribed to someone else;
- Deviating from a prescribed dosage or treatment.
Hoe vaak komt zelfmedicatie voor?
No figures are available for Belgium. Researchers abroad have tried to map this. For example, a 2016 study in the Netherlands found that 18% of the 273 participants had used hormones before they were medically prescribed. Most of the medication was obtained outside official channels, such as online or through another person3.
A follow-up study (2022) reported that 15% of the 727 participants used self-medication, mainly because of the long waiting times in transgender care (48%)4. The researchers emphasize the sensitivity of self-medication and therefore stress that the actual percentage may be higher.
What does the law say about self-medication?
In Belgium, the use and sale of medication are regulated by law. The medication used as gender-affirming hormones is prescription-only. This means you may only purchase and use it if it has been prescribed by a doctor. You can find an overview of this (approved) medication for gender-affirming hormone therapy below:
- Overview of ‘estrogens’ productsExternal linkPDF (in Dutch)
- Overview of ‘anti-androgens’ productsExternal linkPDF (in Dutch)
- Overview of ‘testosterone’ productsExternal linkPDF (in Dutch)
Buying prescription-only medication online without medical supervision is not regulated and can involve risks, both legal and for general health. For this reason, it is discouraged by the Federal Agency for Medicines and Health Products (FAMHP)External link, which supervises the quality, safety and reliability of medication in Belgium.
For minors, the advice of the Order of PhysiciansExternal link additionally applies: medical care for minors with gender incongruence/dysphoria should only be started under the guidance of a multidisciplinary gender team. This is because such guidance requires specific expertise and specialization (such as pediatrics, psychology, endocrinology and child psychiatry), where consultation and critical reflection are essential to ensure a careful approach.
Read more about gender healthcare for minorsExternal link (in Dutch)
Why do some trans people use self-medication?
The reasons why people start self-medicating vary widely and are often intertwined. In the literature, long waiting times in transgender care are most frequently cited as the trigger5. A lack of experienced primary care providers also plays a role, as do negative or stigmatizing experiences within mainstream healthcare6.
For some people, self-medication is a way to bypass strict access requirements for gender-affirming hormone therapy and the so-called “gatekeeping” role7. Other people who self-medicate say that financial barriers, such as the lack of health insurance, push them in this direction8. For minors, it also matters that parents sometimes do not give consent to start hormone therapy9. Finally, the right to self-determination and the desire to have control over one’s own body are also described as motivations10.
These findings come mainly from international research and show that self-medication is rarely the result of a single determining factor. It often arises within a context of structural, social and healthcare-related barriers, combined with a personal need for autonomy and control over one’s own body.
What are the risks of self-medication?
Hormone therapy plays an important and often positive role in the wellbeing of trans, non-binary and/or gender-diverse people11. In addition to the desired effects, gender-affirming hormone therapy also has side effects. It is therefore important to be aware of both aspects.
On the pages below, you can read more about how gender-affirming hormones work, their effects and possible side effects:
- Estrogen and/or anti-androgen treatmentExternal link (in Dutch)
- Testosterone treatmentExternal link (in Dutch)
A brief overview of the (ir)reversible effects of gender-affirming hormone therapy can be found in the tables below:
- Table of effects of estrogens/anti-androgensExternal linkPDF (in Dutch)
- Table of effects of testosteroneExternal linkPDF (in Dutch)
When gender-affirming hormones are used without medical supervision, additional health risks may go unnoticed. Medical supervision is needed to learn which health risks may apply to each person’s unique body. At the same time, it is important to recognize that going without care can also have a negative impact on the mental health of trans and/or non-binary people.
Unregulated medication
Medication ordered online may be mislabeled, expired, or have an unknown or impure composition.
Incorrect dosage
Both too-high and too-low doses can lead to hormonal imbalances, blood pressure problems, mood swings, and metabolic complications. For example, too high a dose of testosterone can lead to an increased number of red blood cells (polycythemia).
Individual physical differences
The effects and risks of gender-affirming hormone therapy can vary greatly from person to person. For some people, general information is not enough to account for individual physical differences and needs. Factors such as age, general health, allergies, lifestyle and biological variations (including variations in sex development (intersex)) play an important role here.
Cardiovascular risks
Estrogens increase the risk of blood clots. A blood clot can, for example, cause a pulmonary embolism, which can be serious and in some cases life-threatening. Read more about how dangerous a pulmonary embolism can beExternal link (in Dutch). In addition, the use of estrogens also increases the risk of stroke and other cardiovascular diseases. This risk is higher in smokers and at a later age (from around 40 years).
Testosterone can affect cholesterol levels and increase the risk of cardiovascular disease, such as a heart attack.
Without medical follow-up, there is a risk that problems are not detected, or detected too late.
Read more about cardiovascular risksExternal link (in Dutch).
Liver and kidney strain
Hormones in pill form in particular can put a strain on the liver. Incorrect dosages increase the likelihood of liver problems and, in rare cases, kidney problems as well.
Unpredictable bodily changes
Gender-affirming hormone therapy comes with multiple effects (see this table for estrogens and this table for testosterone), and bodies can respond to them differently.
It can also come with reduced fertility (read more about the influence of testosterone on fertilityExternal link (in Dutch), the influence of estrogens on fertility, and desire to have children).
Without medical and psychosocial support, there is a risk that you will not be sufficiently prepared for this or supported in it.
Unpredictable psychosocial impact
Gender-affirming hormone therapy aims to reduce distress related to gender incongruence or dysphoria, but in the beginning it can also come with mood swings or a temporary increase in low mood or anxiety. These symptoms are often temporary, but they can be harder to cope with without psychosocial support.
How can the risks of self-medication be reduced?
To limit the possible risks of self-medication as much as possible, medical supervision is recommended. Psychosocial support may also be desirable for some people. The tips below can help reduce certain risks.
1. Inform yourself thoroughly
Before you start hormone therapy, it is important to gather reliable information. Learn about the possible effects, side effects and limitations of hormone therapy. Not all physical changes occur at the same speed. Some changes are permanent, while others are reversible.
Some useful pages and resources you can consult:
- Page: Estrogen and anti-androgen treatment (in Dutch)
- Page: Testosterone treatment (in Dutch)
- Table: (ir)reversible effects of estrogen and anti-androgen treatment PDF(in Dutch)
- Table: (ir)reversible effects of testosterone treatmentPDF (in Dutch)
Be critical of information circulating on social media or internet forums. Personal testimonies can be valuable for learning about other people’s experiences, but they do not replace scientifically and medically grounded information. Every body functions differently. What works for or is experienced by one person does not necessarily have the same effect on someone else. How hormones work and their possible effects depend on various factors (see earlier: What are the risks of self-medication?).
Would you like more information? Contact us free of charge and anonymously:
- by phone: 0800 96 316
- or by email: contact@transgenderinfo.be
2. Involve a healthcare provider
Discuss your situation with a healthcare provider. Ideally, this is your GP and/or an endocrinologist. This provider can assess your health and work with you to determine what is safe and appropriate. A medical evaluation may include, among other things:
- mapping out your medical history and medication use;
- blood tests;
- blood pressure checks;
- additional tests if needed, such as a bone density scan.
Based on this, a healthcare provider can offer careful follow-up, adjust dosages where necessary, or refer you on when appropriate.
Reading tips
- The Dutch patient organization Transvisie has developed a Guide to supporting gender-affirming hormone therapy in primary careExternal linkPDF (in Dutch). It aims to give GPs more background on hormone therapy. Please note: this guide applies to the Dutch context.
- TipsPDF (in Dutch) for how to start the conversation about self-medication as a GP/primary care provider.
3. Get regular medical follow-up
Hormones have an effect on your body. That is why regular follow-up is important. This may include, among other things:
- a blood test;
- monitoring of hormone levels;
- a check of your general health.
Regular follow-up helps to detect possible risks or side effects in time and to adjust the treatment where necessary.
How often? After starting hormone treatment, a first check-up usually takes place after about 3 to 4 months. A second check-up often follows 6 to 9 months later. If the treatment is going well, follow-up can then usually take place once a year or every two years.
This is an average follow-up schedule. How often you are monitored depends on your individual situation and medical history. For certain medical profiles, more frequent follow-up may be needed.
4. Do not stop or adjust your dosage on your own
Always consult a doctor before you stop hormone therapy or change your dosage. Together, you can assess whether a change is needed and how to do it safely.
Stopping temporarily or permanently can be a conscious choice, for example if you want to have children, are preparing for fertility treatment, or do not want any further changes.
In most cases it is safe to stop, as long as you have not had an orchidectomy (removal of the testicles) or an ovariectomy (removal of the ovaries). If you have had one of these procedures, you need to keep taking hormones for life. This prevents a shortage of steroid hormones and reduces risks such as bone loss (osteoporosis).
After stopping, it can take several months before your body starts producing hormones again. Some changes are permanent, while others gradually return. During this period, you may also experience temporary symptoms similar to menopausal symptoms.
Have your hormone levels checked 3 to 6 months after stopping. This shows whether your body has restarted hormone production. If it has not, contact an endocrinologist.
5. Be careful with online medication
Not all websites that offer hormonal medication are reliable. Some products have not been tested in a laboratory, contain substances other than those listed, or may be harmful to your health.
Do you have doubts about a website, or have you had a negative experience? You can report this to medicrime@fagg.be. The Federal Agency for Medicines and Health Products (FAMHP) monitors the quality, safety and effectiveness of medicines.
6. Take a critical look at online care providers
In addition to buying medication entirely on your own, there are also online care providers that offer gender-affirming hormone therapy. These services offer an alternative to mainstream transgender care, with online consultations and shorter waiting times. Although these providers offer hormone therapy, it is important to know that their way of working may differ from that of the multidisciplinary gender teams in hospitals. For example, there is often a lack of clarity about:
- how medical and psychosocial follow-up are handled
- the involvement of different care disciplines (such as endocrinology, psychology, etc.)
- how long-term follow-up and care are organized
The guidelines of the SOC8 of the World Professional Association for Transgender Health (WPATH)External link describe a broad, multidisciplinary approach. In practice, online care models focus mainly on informed consent and a quick start to hormone therapy, which means that not all SOC8 guidelines are often applied.
In addition, some online care providers operate from abroad (both within and outside Europe), which can raise questions about the validity of prescriptions in Belgium, the possibilities for local follow-up by a GP or specialist, and the application of national regulations and quality control.
For some adults, online providers can be an intermediate step when access to mainstream care is difficult. At the same time, it is important to view these services critically and, where possible, to combine them with follow-up by a local healthcare provider (such as a GP or endocrinologist).
More info
- Guide to supporting gender-affirming hormone therapy in primary care (Transvisie, 2025) (in Dutch)External linkPDF
- Testimony of a trans person who self-medicates (De Morgen, 2025) (in Dutch)External link
- Longread by journalism students on ‘Living by your own prescription: The reality of self-medication’ (2026) (in Dutch)External link
- Thematic dossier: LGBTQI+-sensitive practice in general practice (Domus Medica) (in Dutch)External link
- Tips for healthcare providers: how to approach someone who self-medicates (in Dutch)PDF
Sources
- 1
Edenfield, A. C., Holmes, S., & Colton, J. S. (2019). Queering tactical technical communication: DIY HRT. Technical Communication Quarterly, 28(3), 177-191.
Fondén, E. (2020). Do It Yourself Hormone Replacement Therapy In Dissonance With State-Sanctioned Constructions of Gender.
- 2
Rotondi, N. K., Bauer, G. R., Scanlon, K., Kaay, M., Travers, R., & Travers, A. (2013). Nonprescribed hormone use and self-performed surgeries:“do-it-yourself” transitions in transgender communities in Ontario, Canada. American journal of public health, 103(10), 1830-1836.
- 3
Van den Boom, E. M. (2016). Onderzoek Transgenderzorg Nederland [Research transgender care Netherlands]. Stichting Transvisie.
- 4
Zorgvuldig Advies, & Transvisie. (2022). Ervaringen en behoeften van transgender personen in de zorg: Vervolgonderzoek. Uitgevoerd in samenwerking met Amsterdam UMC en Radboudumc, in opdracht van Zorgverzekeraars Nederland en het Ministerie van Volksgezondheid, Welzijn en Sport. Zorgvuldig Advies. https://open.overheid.nl/documenten/ronl-b8614f82bc58342fdd4a40d396385004c86dcfc3/pdf
- 5
Linander, I., Alm, E., Hammarström, A., & Harryson, L. (2017). Negotiating the (bio) medical gaze–Experiences of trans-specific healthcare in Sweden. Social Science & Medicine, 174, 9-16.
Snelgrove, J. W., Jasudavisius, A. M., Rowe, B. W., Head, E. M., & Bauer, G. R. (2012). “Completely out-at-sea” with “two-gender medicine”: a qualitative analysis of physician-side barriers to providing healthcare for transgender patients. BMC health services research, 12(1), 110.
Zorgvuldig Advies & Transvisie. (2022). Ervaringen en behoeften van transgender personen in de zorg: Vervolgonderzoek. Uitgevoerd in samenwerking met Amsterdam UMC en Radboudumc, in opdracht van Zorgverzekeraars Nederland en het Ministerie van Volksgezondheid.
- 6
Metastasio, A., Negri, A., Martinotti, G., & Corazza, O. (2018). Transitioning bodies. The case of self-prescribing sexual hormones in gender affirmation in individuals attending psychiatric services. Brain Sciences, 8(5), 88.
- 7
Baker, J. T., Cusanno, B. R., & Dean, M. (2023). Dilemmas in patient-clinician communication about do-it-yourself hormone therapy: A qualitative study. SSM-Qualitative Research in Health, 3, 100213.
- 8
Stroumsa, D., Crissman, H. P., Dalton, V. K., Kolenic, G., & Richardson, C. R. (2020). Insurance coverage and use of hormones among transgender respondents to a national survey. The Annals of Family Medicine, 18(6), 528-534.
- 9
Clark, B. A., Marshall, S. K., & Saewyc, E. M. (2020). Hormone therapy decision-making processes: Transgender youth and parents. Journal of adolescence, 79, 136-147.
- 10
August-Rae, B. C., Baker, J. T., & Buzzanell, P. M. (2024). “Not just rebellious, it's revolutionary”: Do-it-yourself hormone replacement therapy as Liberatory Harm Reduction. Social Science & Medicine, 345, 116681.
- 11
Aldridge, Z., Patel, S., Guo, B., Nixon, E., Bouman, W. P., Witcomb, G. L., & Arcelus, J. (2021). Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study. Andrology, 9(6), 1808–1816.
Allen, L. R., Watson, L. B., Egan, A. M., & Moser, C. N. (2019). Well-being and suicidality among transgender youth after gender-affirming hormones. Clinical Practice in Pediatric Psychology, 7(3), 302–314.
Bauer, G. R., Scheim, A. I., Pyne, J., Travers, R., & Hammond, R. (2015). Intervenable factors associated with suicide risk in transgender persons: A respondent driven sampling study in Ontario, Canada. BMC Public Health, 15, 525.
Nobili, A., Glazebrook, C., & Arcelus, J. (2018). Quality of life of treatment-seeking transgender adults: A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 19(3), 199–220.
Last reviewed on: .